Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1415
Full Text
Open PDFAbstract
Available in full text
Date
September 8, 2016
Authors
Publisher
American Association for Cancer Research (AACR)